person · Reporting owner

Hill Colin

Disclosed activity across 3 companies

Tapewire entity: 32860
SEC CIK: 0001673192

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
Fulcrum Therapeutics, Inc.FULC · Entity 5969	Director	June 30, 2026	July 02, 2026

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

Fulcrum Therapeutics, Inc.

Report date June 30, 2026 · Filed July 02, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.66 · Expires 2036-06-29	Direct	32,000	Reported balance After 2026-06-30 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2026-06-30 · Grant · Acquired 32,000 · Balance 32,000 F1: This option was granted on June 30, 2026 and is scheduled to vest with respect to all shares on the first anniversary of the grant date or, if earlier, immediately prior to the first annual meeting of stockholders occurring after the grant date, subject to continued service.

Filing footnotes · ownership attribution and instrument terms

F1: This option was granted on June 30, 2026 and is scheduled to vest with respect to all shares on the first anniversary of the grant date or, if earlier, immediately prior to the first annual meeting of stockholders occurring after the grant date, subject to continued service.

Past disclosures · reporting ended (2)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

BIOTELEMETRY, INC.

Report date February 09, 2021 · Filed February 12, 2021

Section 16 reporting ended · disclosed 2021-02-12. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	0	Reported balance After 2021-02-09 transaction · row 1 1 source row Row 1 · 2021-02-09 · Disposition to issuer · Disposed 21,654 · Balance 0 F1: Per the terms of the Agreement and Plan of Merger, dated as of December 18, 2020, among the Company, Philips Holding USA Inc., a Delaware corporation, and Davies Merger Sub, Inc., a Delaware corporation (the "Merger Agreement") and the Offer (as defined in the Merger Agreement), each share of Company common stock was validly tendered for $72.00 per share in cash, without interest and less any applicable withholding taxes. F2: Includes 16,083 restricted stock units that, pursuant to the Merger Agreement, were cancelled at the Effective Time of the Merger (both as defined in the Merger Agreement) and converted into the right to receive $72.00 per share in cash, less any applicable withholding taxes.

Filing footnotes · ownership attribution and instrument terms

F1: Per the terms of the Agreement and Plan of Merger, dated as of December 18, 2020, among the Company, Philips Holding USA Inc., a Delaware corporation, and Davies Merger Sub, Inc., a Delaware corporation (the "Merger Agreement") and the Offer (as defined in the Merger Agreement), each share of Company common stock was validly tendered for $72.00 per share in cash, without interest and less any applicable withholding taxes.

F2: Includes 16,083 restricted stock units that, pursuant to the Merger Agreement, were cancelled at the Effective Time of the Merger (both as defined in the Merger Agreement) and converted into the right to receive $72.00 per share in cash, less any applicable withholding taxes.

PPD, Inc.

Report date December 08, 2021 · Filed December 08, 2021

Section 16 reporting ended · disclosed 2021-12-08. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	0	Reported balance After 2021-12-08 transaction · row 1 1 source row Row 1 · 2021-12-08 · Disposition to issuer · Disposed 16,330 · Balance 0 F1: On 12/08/2021, Thermo Fisher Scientific Inc., a Delaware corporation ("Buyer"), acquired the Issuer pursuant to a certain Agreement and Plan of Merger entered into by and among the Issuer, Buyer and Powder Acquisition Corp., a Delaware corporation and wholly-owned subsidiary of Buyer ("Merger Sub"), dated as of April 15, 2021 (the "Merger Agreement"). In accordance with the Merger Agreement, the Issuer merged with and into Merger Sub, with the Issuer surviving such merger as a wholly-owned subsidiary of Buyer (the "Merger"). F2: Includes 2,164 shares of common stock subject to a restricted stock unit grant (the "RSUs") which provided for vesting on the earlier of the one-year anniversary of the grant date and the date of the next regularly scheduled annual meeting of stockholders of the Issuer. At the effective time of the Merger, the RSUs were cancelled and converted into the right to receive an amount of cash equal to the Merger Consideration (as defined below) multiplied by the number of restricted stock units being so canceled and converted. F3: At the effective time of the Merger, each issued and outstanding share of the Issuer's common stock (other than certain excluded shares) automatically converted into the right to receive $47.50 in cash (the "Merger Consideration").

Filing footnotes · ownership attribution and instrument terms

F1: On 12/08/2021, Thermo Fisher Scientific Inc., a Delaware corporation ("Buyer"), acquired the Issuer pursuant to a certain Agreement and Plan of Merger entered into by and among the Issuer, Buyer and Powder Acquisition Corp., a Delaware corporation and wholly-owned subsidiary of Buyer ("Merger Sub"), dated as of April 15, 2021 (the "Merger Agreement"). In accordance with the Merger Agreement, the Issuer merged with and into Merger Sub, with the Issuer surviving such merger as a wholly-owned subsidiary of Buyer (the "Merger").

F2: Includes 2,164 shares of common stock subject to a restricted stock unit grant (the "RSUs") which provided for vesting on the earlier of the one-year anniversary of the grant date and the date of the next regularly scheduled annual meeting of stockholders of the Issuer. At the effective time of the Merger, the RSUs were cancelled and converted into the right to receive an amount of cash equal to the Merger Consideration (as defined below) multiplied by the number of restricted stock units being so canceled and converted.

F3: At the effective time of the Merger, each issued and outstanding share of the Issuer's common stock (other than certain excluded shares) automatically converted into the right to receive $47.50 in cash (the "Merger Consideration").

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
June 30, 2026 Filed Jul 2, 2026 20:30 UTC	Fulcrum Therapeutics, Inc. FULC · Entity 5969	GrantStock Option (right to buy) · Derivative	32,000	$0.00 Strike: $3.66	$0.00	Disclosure SEC source: 0001193125-26-294683 · ownership.xml · derivative · entry 1 Hill Colin · CIK 0001673192 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 32,000 Underlying: Common Stock · 32,000 shares Expires 2036-06-29 F1 · derivative.exercise_date: This option was granted on June 30, 2026 and is scheduled to vest with respect to all shares on the first anniversary of the grant date or, if earlier, immediately prior to the first annual meeting of stockholders occurring after the grant date, subject to continued service. Read SEC document
June 26, 2025 Filed Jun 30, 2025 20:15 UTC	Fulcrum Therapeutics, Inc. FULC · Entity 5969	GrantStock Option (right to buy) · Derivative	36,000	$0.00 Strike: $7.38	$0.00	Disclosure SEC source: 0000950170-25-091580 · ownership.xml · derivative · entry 1 Hill Colin · CIK 0001673192 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 36,000 Underlying: Common Stock · 36,000 shares Expires 2035-06-25 F1 · derivative.exercise_date: This option was granted on June 26, 2025 and is scheduled to vest with respect to all shares on the first anniversary of the grant date or, if earlier, immediately prior to the first annual meeting of stockholders occurring after the grant date, subject to continued service. Read SEC document
June 17, 2024 Filed Jun 18, 2024 20:15 UTC	Fulcrum Therapeutics, Inc. FULC · Entity 5969	GrantStock Option (right to buy) · Derivative	60,000	$0.00 Strike: $7.00	$0.00	Disclosure SEC source: 0000950170-24-074868 · ownership.xml · derivative · entry 1 Hill Colin · CIK 0001673192 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 60,000 Underlying: Common Stock · 60,000 shares Expires 2034-06-16 F1 · derivative.exercise_date: This option was granted on June 17, 2024 and is scheduled to vest in equal monthly installments until June 17, 2027, subject to continued service. Read SEC document
December 08, 2021 Filed Dec 8, 2021 21:41 UTC	PPD, Inc. PPD · Entity 15247	Disposition to issuerCommon Stock	16,330	$47.50	$775,675.00	Disclosure SEC source: 0001437749-21-028116 · rdgdoc.xml · nonDerivative · entry 1 Hill Colin · CIK 0001673192 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: On 12/08/2021, Thermo Fisher Scientific Inc., a Delaware corporation ("Buyer"), acquired the Issuer pursuant to a certain Agreement and Plan of Merger entered into by and among the Issuer, Buyer and Powder Acquisition Corp., a Delaware corporation and wholly-owned subsidiary of Buyer ("Merger Sub"), dated as of April 15, 2021 (the "Merger Agreement"). In accordance with the Merger Agreement, the Issuer merged with and into Merger Sub, with the Issuer surviving such merger as a wholly-owned subsidiary of Buyer (the "Merger"). F2 · shares: Includes 2,164 shares of common stock subject to a restricted stock unit grant (the "RSUs") which provided for vesting on the earlier of the one-year anniversary of the grant date and the date of the next regularly scheduled annual meeting of stockholders of the Issuer. At the effective time of the Merger, the RSUs were cancelled and converted into the right to receive an amount of cash equal to the Merger Consideration (as defined below) multiplied by the number of restricted stock units being so canceled and converted. F2 · price: Includes 2,164 shares of common stock subject to a restricted stock unit grant (the "RSUs") which provided for vesting on the earlier of the one-year anniversary of the grant date and the date of the next regularly scheduled annual meeting of stockholders of the Issuer. At the effective time of the Merger, the RSUs were cancelled and converted into the right to receive an amount of cash equal to the Merger Consideration (as defined below) multiplied by the number of restricted stock units being so canceled and converted. F3 · price: At the effective time of the Merger, each issued and outstanding share of the Issuer's common stock (other than certain excluded shares) automatically converted into the right to receive $47.50 in cash (the "Merger Consideration"). Read SEC document
April 23, 2021 Filed Apr 27, 2021 20:13 UTC	PPD, Inc. PPD · Entity 15247	GrantCommon Stock	2,164	$0.00	$0.00	Disclosure SEC source: 0001628280-21-007731 · wf-form4_161955433224243.xml · nonDerivative · entry 1 Hill Colin · CIK 0001673192 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,330 F1 · kind: Represents a grant of restricted stock units which will vest on the earlier of the one-year anniversary of the grant date and the date of the next regularly scheduled annual meeting of stockholders of the issuer, subject to continued service through the vesting date. Read SEC document
February 09, 2021 Filed Feb 12, 2021 02:44 UTC	BIOTELEMETRY, INC. BEAT · Entity 142764	Disposition to issuerCommon Stock	21,654	$72.00	$1,559,088.00	Disclosure SEC source: 0000899243-21-006168 · doc4.xml · nonDerivative · entry 1 Hill Colin · CIK 0001673192 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · shares: Per the terms of the Agreement and Plan of Merger, dated as of December 18, 2020, among the Company, Philips Holding USA Inc., a Delaware corporation, and Davies Merger Sub, Inc., a Delaware corporation (the "Merger Agreement") and the Offer (as defined in the Merger Agreement), each share of Company common stock was validly tendered for $72.00 per share in cash, without interest and less any applicable withholding taxes. F2 · shares: Includes 16,083 restricted stock units that, pursuant to the Merger Agreement, were cancelled at the Effective Time of the Merger (both as defined in the Merger Agreement) and converted into the right to receive $72.00 per share in cash, less any applicable withholding taxes. Read SEC document
September 21, 2020 Filed Sep 23, 2020 20:44 UTC	PPD, Inc. PPD · Entity 15247	SaleCommon stock	1,722	$31.28	$53,868.47	Disclosure SEC source: 0000899243-20-026092 · doc4.xml · nonDerivative · entry 1 Hill Colin · CIK 0001673192 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,166 F1 · price: This amount represents the $32.25 secondary public offering price per share of the Common Stock of the Issuer less the underwriting discount of $0.9675 per share. Read SEC document
May 13, 2020 Filed May 15, 2020 20:50 UTC	PPD, Inc. PPD · Entity 15247	GrantCommon stock	3,728	$0.00	$0.00	Disclosure SEC source: 0000899243-20-013240 · doc4.xml · nonDerivative · entry 1 Hill Colin · CIK 0001673192 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,888 F1 · kind: Represents a grant of restricted stock units which will vest on the earlier of the one-year anniversary of the grant date and the date of the next regularly scheduled annual meeting of stockholders of the issuer, subject to continued service through the vesting date. Read SEC document
May 11, 2020 Filed May 13, 2020 21:31 UTC	BIOTELEMETRY, INC. BEAT · Entity 142764	GrantCommon Stock	2,863	$0.00	$0.00	Disclosure SEC source: 0001574774-20-000085 · wf-form4_158940546813477.xml · nonDerivative · entry 2 Hill Colin · CIK 0001673192 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,654 F2 · shares: Grant of restricted stock units that, subject to certain exceptions, will vest in full on the first anniversary of the grant date. Read SEC document
May 03, 2020 Filed May 13, 2020 21:31 UTC	BIOTELEMETRY, INC. BEAT · Entity 142764	Tax withholdingCommon Stock	19	$45.51	$864.69	Disclosure SEC source: 0001574774-20-000085 · wf-form4_158940546813477.xml · nonDerivative · entry 1 Hill Colin · CIK 0001673192 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,791 F1 · shares: Represents shares withheld to cover taxes in connection with the Reporting Person's May 3, 2019, restricted stock unit grant. Read SEC document
February 10, 2020 Filed Feb 12, 2020 21:15 UTC	PPD, Inc. PPD · Entity 15247	GrantCommon stock	12,160	Not disclosed	Not disclosed	Disclosure SEC source: 0000899243-20-004249 · doc4.xml · nonDerivative · entry 2 Hill Colin · CIK 0001673192 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,160 F1 · price: Upon the completion of the initial public offering of PPD, Inc. (the "Issuer"), all shares of the Issuer's non-voting common stock automatically converted into shares of the Issuer's voting common stock on a one-for-one basis. Read SEC document
February 10, 2020 Filed Feb 12, 2020 21:15 UTC	PPD, Inc. PPD · Entity 15247	Disposition to issuerNon-voting common stock	12,160	Not disclosed	Not disclosed	Disclosure SEC source: 0000899243-20-004249 · doc4.xml · nonDerivative · entry 1 Hill Colin · CIK 0001673192 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · security: Upon the completion of the initial public offering of PPD, Inc. (the "Issuer"), all shares of the Issuer's non-voting common stock automatically converted into shares of the Issuer's voting common stock on a one-for-one basis. F1 · price: Upon the completion of the initial public offering of PPD, Inc. (the "Issuer"), all shares of the Issuer's non-voting common stock automatically converted into shares of the Issuer's voting common stock on a one-for-one basis. Read SEC document
May 06, 2019 Filed May 7, 2019 22:13 UTC	BIOTELEMETRY, INC. BEAT · Entity 142764	Tax withholdingCommon Stock	25	$52.87	$1,321.75	Disclosure SEC source: 0001574774-19-000042 · wf-form4_155726718905307.xml · nonDerivative · entry 2 Hill Colin · CIK 0001673192 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,810 F2 · shares: Represents shares withheld to cover taxes in connection with the Reporting Person's May 4, 2018, restricted stock unit grant. Read SEC document
May 03, 2019 Filed May 7, 2019 22:13 UTC	BIOTELEMETRY, INC. BEAT · Entity 142764	GrantCommon Stock	2,424	$0.00	$0.00	Disclosure SEC source: 0001574774-19-000042 · wf-form4_155726718905307.xml · nonDerivative · entry 1 Hill Colin · CIK 0001673192 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,835 F1 · shares: Grant of restricted stock units that, subject to certain exceptions, will vest in full on the first anniversary of the grant date. Read SEC document
May 04, 2018 Filed May 8, 2018 20:20 UTC	BIOTELEMETRY, INC. BEAT · Entity 142764	GrantCommon Stock	3,191	$0.00	$0.00	Disclosure SEC source: 0001574774-18-000037 · wf-form4_152581076187839.xml · nonDerivative · entry 1 Hill Colin · CIK 0001673192 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,411 F1 · shares: Grant of restricted stock units that, subject to certain exceptions, will vest in full on the first anniversary of the grant date. Read SEC document
May 12, 2017 Filed May 16, 2017 21:27 UTC	BIOTELEMETRY, INC. BEAT · Entity 142764	GrantCommon Stock	2,842	$0.00	$0.00	Disclosure SEC source: 0001209191-17-032815 · doc4.xml · nonDerivative · entry 1 Hill Colin · CIK 0001673192 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,220 F1 · shares: Represents shares of the Issuer's common stock underlying restricted stock units (RSUs) awarded to the Reporting Person. The RSUs shall vest annually following the award date. In the event of the occurrence of the Reporting Person's death, Disability (within the meaning of such term under section 409A(a)(2)(C) of the Internal Revenue Code of 1986, as amended (the "Code")), "separation from service" (within the meaning of such term under Code section 409A(a)(2)(A)(i)) or a 409A Change in Control Event (as defined in the award agreement) prior to the full vesting date, all outstanding RSUs shall be fully vested. The shares of common stock underlying the RSUs will be issued when the RSUs vest. F2 · balance_after: Includes 2,842 shares of the Issuer's common stock subject to the reported RSU award. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.